Abstract
It is still unclear whether reduced-intensity stem cell transplantation (RIST) from an HLA-mismatched related donor is feasible for hematologic malignancies. In the current study on the use of antithymocyte globulin (ATG) in 13 patients, we focused on this issue by evaluating regimenrelated toxicities, engraftment, graft-versus-host disease (GVHD), infection, and overall survival. Our results suggest that this procedure may be acceptable for patients without a matched related donor.
| Original language | English |
|---|---|
| Pages (from-to) | 115-117 |
| Number of pages | 3 |
| Journal | Haematologica |
| Volume | 88 |
| Issue number | 1 |
| Publication status | Published - 2003 Feb 1 |
| Externally published | Yes |
Fingerprint
Keywords
- Engraftment
- GVHD
- Mismatched reduced-intensity stem cell transplantation
ASJC Scopus subject areas
- Hematology
Cite this
The feasibility of reduced-intensity allogeneic hematopoietic stem cell transplantation from a related donor with HLA one-antigen with or without one-allele mismatch. / Nakai, Kunihisa; Mineishi, Shin; Kami, Masahiro; Konda, Yoshinobu; Tanosaki, Ryuji; Takaue, Yoichi.
In: Haematologica, Vol. 88, No. 1, 01.02.2003, p. 115-117.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The feasibility of reduced-intensity allogeneic hematopoietic stem cell transplantation from a related donor with HLA one-antigen with or without one-allele mismatch
AU - Nakai, Kunihisa
AU - Mineishi, Shin
AU - Kami, Masahiro
AU - Konda, Yoshinobu
AU - Tanosaki, Ryuji
AU - Takaue, Yoichi
PY - 2003/2/1
Y1 - 2003/2/1
N2 - It is still unclear whether reduced-intensity stem cell transplantation (RIST) from an HLA-mismatched related donor is feasible for hematologic malignancies. In the current study on the use of antithymocyte globulin (ATG) in 13 patients, we focused on this issue by evaluating regimenrelated toxicities, engraftment, graft-versus-host disease (GVHD), infection, and overall survival. Our results suggest that this procedure may be acceptable for patients without a matched related donor.
AB - It is still unclear whether reduced-intensity stem cell transplantation (RIST) from an HLA-mismatched related donor is feasible for hematologic malignancies. In the current study on the use of antithymocyte globulin (ATG) in 13 patients, we focused on this issue by evaluating regimenrelated toxicities, engraftment, graft-versus-host disease (GVHD), infection, and overall survival. Our results suggest that this procedure may be acceptable for patients without a matched related donor.
KW - Engraftment
KW - GVHD
KW - Mismatched reduced-intensity stem cell transplantation
UR - http://www.scopus.com/inward/record.url?scp=0037311030&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037311030&partnerID=8YFLogxK
M3 - Article
VL - 88
SP - 115
EP - 117
JO - Haematologica
JF - Haematologica
SN - 0390-6078
IS - 1
ER -